|Principal Investigator/ Physician||Rodney Rocconi, MD|
|Contact Email||MCI Clinical Trials|
Protocol: A Randomized, Intra-patient Crossover, Safety,Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients with Advanced Gynecological Cancers
Inclusion Criteria: Successful manufacturing of at least 4 vials of Vigil; Failure to meet the eligibililty criteria for Protocol CL-PTL-119 due to i) histology of ovarian cancer and failure to achieve a complete clinical response following primary debulking surgery and standard paclitaxel/carboplatin therapy OR, ii) a histologic diagnosis of another gynecologic malignancy which is not ovarian cancer; ECOG performance status (PS) ≤ 1; Estimated survival ≥ 6 months; Measureable or evaluable disease; Adequate organ and bone marrow function.
Exclusion Criteria: Rceived more than two additional chemotherapy regimens for platinum resistant/refractory ovarian cancer, after their initial treatment with paclitaxel/carboplatin, OR have received more than two additional chemotherapy regimens for the treatment of another gynecologic malignancy; Participation in another clinical study with an investigational product within the last 3 weeks prior to study start; Patients with autoimmune diseases are excluded from enrollment with the exception of patients with hypothyroidism on stable thyroxine replacement, and patients with T1DM on stable insulin replacement; Receipt of steroid therapy within the 2 weeks of the first dose of study therapy; Post-surgery complication; Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.
Clinical Trials.Gov Link: https://clinicaltrials.gov/ct2/show/NCT03073525?term=CL-PTL-126&recrs=a&rank=1
© 2018 USA Health System